Baseline demographic and clinical characteristics of patients with uveitis analysed during the COVID-19 pandemic
| Parameter | All patients (n=176; 284 eyes) | |
|---|---|---|
| Mean age, years±SD | 33±17.1 | |
| Number of males, n (%) | 68 (38.6) | |
| Number of patients with bilateral disease, n (%) | 108 (61.4) | |
| Anatomical location of uveitis | ||
| Anterior, n (%) | 45 (25.6) | |
| Intermediate, n (%) | 20 (11.4) | |
| Posterior, n (%) | 54 (31.2) | |
| Panuveitis, n (%) | 57 (32.4) | |
| Aetiological diagnosis | ||
| Undifferentiated uveitis, n (%) | 64 (36.4) | |
| Retinal vasculitis, n (%) | 23 (13.5) | |
| Sarcoidosis, n (%) | 15 (8.5) | |
| HLA B27-related uveitis, n (%) | 13 (7.4) | |
| Vogt-Koyanagi-Harada’s disease, n (%) | 12 (6.8) | |
| Behcet’s uveitis, n (%) | 10 (5.7) | |
| Serpiginous choroiditis, n (%) | 10 (5.7) | |
| Others, n (%) | 29 (16.5) | |
| Number of eyes with active uveitis (number of patients) | 121 (90) | |
| Ongoing medications | ||
| Topical corticosteroids (number of eyes), n (%) | 73 (25.7) | |
| Topical cycloplegic agents (number of eyes), n (%) | 56 (19.7) | |
| Topical NSAIDS (number of eyes), n (%) | 44 (15.5) | |
| Oral corticosteroids (number of subjects), n (%) | 94 (53.4) | |
| Intravenous corticosteroids (number of subjects), n (%) | 11 (6.2) | |
| Oral azathioprine (number of subjects), n (%) | 61 (34.7) | |
| Oral mycophenolate mofetil (number of subjects), n (%) | 24 (13.6) | |
| Oral/subcutaneous methotrexate (number of subjects), n (%) | 71 (40.3) | |
| Oral tacrolimus (number of subjects), n (%) | 2 (1.1) | |
| Oral ciclosporin (number of subjects), n (%) | 1 (0.6) | |
| Oral cyclophosphamide (number of subjects), n (%) | 1 (0.6) | |
| Subcutaneous adalimumab (number of subjects), n (%) | 16 (9.1) | |
| Intravenous tocilizumab (number of subjects), n (%) | 3 (1.7) | |
| Intravenous rituximab (number of subjects), n (%) | 2 (1.1) | |
| Prevalence of complications of uveitis | ||
| Band-shaped keratopathy (n, %) | 5 (1.8) | |
| Secondary cataract (n, %) | 49 (17.2) | |
| Macular oedema (n, %) | 41 (14.4) | |
| Optic nerve oedema (n, %) | 20 (7.0) | |
| Epiretinal membrane (n, %) | 19 (6.7) | |
| Ocular hypertension/glaucoma (n, %) | 17 (6.0) | |